参考文献/References:
[1] Smith M A.Outcomes for children and adolescents with cancer: challenges for the twenty-first century[J].J Clin Oncol, 2010, 28(15):2625-2634.
[2] McKeown M R, Bradner J E.Therapeutic strategies to inhibit MYC[J].Cold Spring Harb Perspect Med, 2014, 4(10):12-18.
[3] 翁克贵,蒋勇,王颖.干扰 c-myc 基因表达增强人胰腺癌细胞对吉西他滨和卡铂的敏感性[J].肿瘤药学, 2017, 7(3): 273-277.
[4] 赵迎春，冯娥，田云云.骨肉瘤的免疫检查点及其抑制剂应用的研究进展[J].广西医学, 2020, 42(7): 891-894.
[5] 林泽鑫,林欣.免疫检测点抑制剂及其生物标志物在晚期实体肿瘤中的研究进展[J].中国实用医药, 2019, 14(2): 190-193.
[6] 周灵，谢琳，廖冶丹，等.骨肉瘤转移机制研究进展[J].中华转移性肿瘤杂志，2019，2(3):55-59.
[7] Wang O, Yang F, Liu Y, et al.C-MYC-induced upregulation of lncRNA SNHG12 regulates cell proliferation, apoptosis and migration in triple-negative breast cancer[J].Am J Transl Res, 2017, 9(2): 533-545.
[8] 施锦涛，张凯，张芮浩，等.PD-1/PD-L1轴与骨肉瘤治疗研究进展[J].解放军医学杂志, 2021, 46(1): 89-94.
[9] Shimizu T, Fuchimoto Y, Fukuda K, et al.The effect of immune checkpoint inhibitors on lung metastases of osteosarcoma[J].J Pediatr Surg, 2017, 52(12): 2047-2050.
[10] Casey S C，Tong L，Li Y，et al.MYC regulates the antitumor immune response through CD47 and PD-L1[J].Science,2016,352(6282):227-231.
[11] 黄杰中,陈敬恒.c-myc蛋白及凋亡抑制、促进因子在骨肉瘤中的检测价值探究[J].中国医学创新, 2021, 18(9):138-142.
[12] Zheng B,Ren T,Huang Y,et al.PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse[J].J HematolOncol, 2018, 11(1): 16.